Compare ECBK & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ECBK | SKYE |
|---|---|---|
| Founded | 1919 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.3M | 23.3M |
| IPO Year | 2022 | 2013 |
| Metric | ECBK | SKYE |
|---|---|---|
| Price | $16.90 | $0.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 9.5K | ★ 340.2K |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 95.83 | N/A |
| EPS | ★ 0.94 | N/A |
| Revenue | ★ $598,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.01 | ★ N/A |
| Revenue Growth | ★ 3.64 | N/A |
| 52 Week Low | $14.70 | $0.57 |
| 52 Week High | $20.05 | $5.75 |
| Indicator | ECBK | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 51.92 | 52.16 |
| Support Level | $15.87 | $0.68 |
| Resistance Level | $17.50 | $0.83 |
| Average True Range (ATR) | 0.45 | 0.04 |
| MACD | 0.10 | 0.01 |
| Stochastic Oscillator | 83.21 | 84.95 |
ECB Bancorp Inc operates as a bank holding company of Everett Co-operative Bank. The firm through its subsidiary engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, and multifamily real estate loans, construction and land loans and home equity lines of credit.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.